Normax Press Room
Normax Biomed and Oyster Venture Partners Join Forces to Revolutionize Cancer Treatment with Personalized mRNA Immunotherapy
Normax Biomed has launched a capital raise campaign for up to £15 million in Series A funding for the deployment of Educated Antigen Receptor Therapy (EARTh) GMP Process for personalized mRNA cancer vaccine production in GMP clean room located in the Medical Technology Innovation Center (MTIF) at Nottingham Trent University Clifton Campus May 13, 2024, 12:00 PM Greenwich Mean Time (GMT) - PRESS RELEASE. NOT AN OFFER. SEE DISCLAIMER. Nottingham, UK – [...]
Normax partners with Medical Technologies Innovation Facility at Nottingham Trent University to offer access to BioXp system by Telesis Bio
The collaboration agreement with Normax Biomed Ltd, will enable The Medical Technologies Innovation Facility at Nottingham Trent University to accelerate the development and discovery of new mRNA vaccines and gene therapies. 24 January 2023 – Normax Biomed Limited (“Normax”) has launched a partnership with the Medical Technologies Innovation Facility (MTIF) at Nottingham Trent University (NTU) to offer access to its BioXPTM system by Telesis Bio Inc. and to innovate in RNA [...]
Normax secures €300,000,000 capital commitment from Global Emerging Markets (GEM) for research and development and manufacturing of mRNA Vaccines for transformative global social impact
Normax plans to use capital finance to scale mRNA Vaccine Research and Development with Vax Factory Manufacturing for Transformative Social Impact on Infectious Diseases, Rare Diseases, Cancers and Pandemic Preparedness July 11, 2022, 12:00 PM Greenwich Mean Time (GMT) - PRESS RELEASE. NOT AN OFFER. SEE DISCLAIMER. DUBLIN, Ireland -- The mRNA vaccine technology company Normax Biomed Limited (“Normax”), today announced a €300 Million investment commitment from GEM Global Yield LLC SCS (“GEM”), [...]
